{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012030","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.778305+00:00","generated_at":"2026-06-04T05:21:53.754597+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Celcuity extends Term C Loan draw deadline to June 1, 2024 via Second Amendment with Innovatus","bullets":["Second Amendment extends Term C Draw Period from April 1, 2024 to June 1, 2024.","$10M Term C Loan available upon achievement of Term C Milestone and satisfaction of conditions.","First $15M loan drawn April 2021; $20M additional loan drawn December 2022.","No other changes to Loan Agreement; up to $75M total borrowing capacity unchanged.","Representations and warranties reaffirmed; no event of default (except existing defaults)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012030","json":"https://secwatch.observer/filing/0001493152-24-012030.json","markdown":"https://secwatch.observer/filing/0001493152-24-012030.md","text":"https://secwatch.observer/filing/0001493152-24-012030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224012030/0001493152-24-012030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224012030/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:21:53.754597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69dc9be9f333e9d8f4287b1c9d4d876aad61737c","claim":"Celcuity Inc. amended credit facility of up to $75.0 million with Innovatus Life Sciences Lending Fund I, L.P..","evidence_excerpt":"Amendment, shall be collectively referred to herein as the “Amended Loan Agreement”). As previously disclosed, the Amended Loan Agreement may provide the Company with up to $75.0 million through funding of up to five term loans. Funding of the first $15.0 million term loan occurred on April 8, 2021 in connection with entering into the original Loan","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224012030/0001493152-24-012030-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $75.0 million"},{"label":"Counterparty","value":"Innovatus Life Sciences Lending Fund I, L.P."},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"9f65540e13adb20db5109f30ec6a3f8b68cf5925","claim":"Celcuity Inc. amended Second Amendment with Innovatus Life Sciences Lending Fund I, L.P. (effective 2024-03-29).","evidence_excerpt":"On March 29, 2024, Celcuity Inc. (the “Company”) entered into a Second Amendment (the “Second Amendment”) to its existing Loan and Security Agreement (the “Loan Agreement”), dated April 8, 2021, between the Company and Innovatus Life Sciences Lending Fund I, L.P., a Delaware limited partnership (“Innovatus\")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224012030/0001493152-24-012030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Innovatus Life Sciences Lending Fund I, L.P."},{"label":"Effective","value":"2024-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}